GlassScriptPhysician profile
Gladys Torres
NPI 1396278867
$7,869.10
in general payments reported to CMS, 2019-2025
33 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,869 · 2022: $1,505 · 2023: $1,576 · 2024: $1,573 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,492 · Education: $3.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,492.03 |
| Education | $3.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,318.77 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $785.65 | 2021 | |
| Pfizer INC. | $707.33 | 2023-2025 | |
| Sk Life Science, INC. | $642.85 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $604.98 | 2021-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $482.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $413.86 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $373.99 | 2022-2024 | Ingrezza, Ongentys |
| Eisai INC. | $360.40 | 2021-2024 | |
| Ucb, INC. | $289.63 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $214.83 | 2023-2024 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $200.22 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Biogen, INC. | $174.97 | 2021-2025 | Skyclarys |
| Sunovion Pharmaceuticals INC. | $145.74 | 2021-2022 | |
| Lundbeck LLC | $141.62 | 2024-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $141.58 | 2021-2024 | Inbrija, Ampyra |
| Kyowa Kirin, INC. | $127.79 | 2021-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $74.01 | 2024-2025 | Inbrija, Ampyra |
| Neurelis, INC. | $73.44 | 2024 | Valtoco |
| Tanabe Pharma America, INC. | $68.00 | 2023-2025 | Radicava |
| Amneal Pharmaceuticals LLC | $65.15 | 2021-2025 | Crexont |
| Lilly USA, LLC | $60.46 | 2021-2023 | Amyvid |
| Aprecia Pharmaceuticals, LLC | $57.52 | 2022 | |
| Mdd US Operations, LLC | $54.45 | 2024-2025 | Apokyn |
| Aucta Pharmaceuticals, INC. | $48.58 | 2024-2025 | Motpoly Xr |
| Janssen Biotech, INC. | $41.92 | 2025 | |
| Alexion Pharmaceuticals, INC. | $41.70 | 2021 | |
| Idorsia Pharmaceuticals US INC | $37.29 | 2023 | Quviviq |
| Avion Pharmaceuticals | $32.84 | 2023 | Dhivy |
| Astrazeneca Pharmaceuticals LP | $28.85 | 2021 | |
| Bioprotect Medical, INC. | $26.56 | 2025 | Bioprotect Balloon Implant System |
| Livanova USA, INC. | $18.04 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Evoke Pharma, INC. | $14.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gladys Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.